RE:RE:RE:RE:RE:RE:RE:ONCY to make an "Oral Presentation" on Bracelet-1 at ASCOjimsenior - this is the abstract summary authored by Dr. Amy Clark et al. from February 15, 2021 that you are referring to and here is an excerpt ....
"A subsequent window of opportunity study in early breast cancer has shown that pelareorep can indeed promote an adaptive immune response in breast cancer tissue, enhancing CD8+ T cell infiltration and upregulating PD-L1 expression, correlating with high levels of viral replication in HR+/HER2- tumor tissue (Manso et al, 2020). Moreover, high levels of peripheral T cell clonality (PTCC) have been identified as a candidate blood-based on-treatment biomarker for pelareorep therapy, further highlighting the role of an adaptive immune response in driving pelareorep mediated efficacy (Mahalingam et al, 2020; Manso et al, 2020). Thus, BRACELET-1 will test the hypothesis that pelareorep mediated priming of an adaptive immune response will be synergistic with checkpoint blockade therapy in HR+/HER2- mBC. Moreover, BRACELET-1 will further assess PTCC as an on-treatment biomarker. The overall goal of this study is to expand the number of mBC patients who can benefit from better immunotherapy."
https://aacrjournals.org/cancerres/article/81/4_Supplement/OT-13-02/647903/Abstract-OT-13-02-Bracelet-1-pre0113-A-study-to
So it now appears that Dr. Amy Clark will be presenting the positive results from this work.